

To: CN=Jerry D Clewell/OU=AM/O=LLY@Lilly
CC: CN=Robert W Baker/OU=AM/O=LLY@Lilly; CN=Patrizia Cavazzoni/OU=AM/O=LLY@Lilly;
CN=Vicki Poole Hoffmann/OU=AM/O=LLY@Lilly; CN=Matthew R Pike/OU=AM/O=LLY@Lilly;
CN=Patrick A Toalson/OU=AM/O=LLY@Lilly
Date: 09/13/2002 11:44:20 AM
From: CN=Robert A Browne/OU=AM/O=LLY
Subject: Re: Label changes related to hyperglycemia

I have not heard of any such plans. Maybe some of the cc's can comment. Bob

Robert A. Browne MD, FACP
Senior Outcomes Research Advisor
U.S. Outcomes Research
Eli Lilly and Company
Lilly Corporate Center
Mail Drop 4025
Indianapolis, IN 46285
Phone: 317-276-9145
Fax: 317-277-7444
E-mail: browne_robert_a@lilly.com

Jerry D Clewell

09/13/2002 09:18 AM

To: Robert A Browne/AM/LLY@Lilly
cc:
Subject: Re: Label changes related to hyperglycemia

Hi Bob and Pat,

Thanks for forwarding this. It's very important for us to know what the regulatory agencies are thinking. But is there any discussion of sending out a Dear Dr. letter that lays all the facts i.e. epidemiologic and clinical information? I ask because at the end of the day, there's a credibility concern among many in the medical community that the FDA hasn't moved fast enough or aggressive enough with drug safety issues (i.e. Rezulin). It would seem to me that a summary of the actual science would go a long way in educating prescribers on the facts, and help alleviate any concerns that clinicians and customers have that Lilly may not be acting the most forthcoming manner to help them know and understand the actual evidence. In other words, it's not uncommon for us in the field to hear from customers that (they perceive) Lilly is dodging

Page: 1 of 3

the issue or hiding the truth rather than giving them the answers that matter on how to act and react to concerns.

jc

Robert A Browne

09/13/2002 08:58 AM

To: Don P Buesching/AM/LLY@Lilly, Jerry D Clewell/AM/LLY@Lilly, Sheila M Thomas/AM/LLY@Lilly, Anne Ogostalick/AM/LLY@Lilly, Diane M Flickinger/AM/LLY@Lilly, Amy L Dreibelbis/AM/LLY@Lilly, Danielle L Loosbrock/AM/LLY@Lilly, Shalini Purwar/AM/LLY@Lilly, Trina Clark/AM/LLY@Lilly, Eric G Klein/AM/LLY@Lilly, Allen Nyhuis/AM/LLY@Lilly, Baojin Zhu/AM/LLY@Lilly, Beth L Barber/AM/LLY@Lilly, Christine E Eickhoff/AM/LLY@Lilly, David L Van Brunt/AM/LLY@Lilly, Eric Edgell/AM/LLY@Lilly, Frank Ernst/AM/LLY@Lilly, Haya Ascher-Svanum/AM/LLY@Lilly, Janet L Ramsey/AM/LLY@Lilly, Jessica N Broderick/AM/LLY@Lilly, Karl Gregor/AM/LLY@Lilly, Madhav Namjoshi/AM/LLY@Lilly, Martin Marciniak/AM/LLY@Lilly, Michael D Stensland/AM/LLY@Lilly, Mickael Lothgren/EMA/LLY@Lilly, P Joseph Gibson/AM/LLY@Lilly, Robert L Obenchain/AM/LLY@Lilly, Sandra Tunis/AM/LLY@Lilly, Zhongyun Zhao/AM/LLY@Lilly, Liesl Marie Cooper/AM/LLY@Lilly, Tom E Hughes/AM/LLY@Lilly

cc:

Subject: Label changes related to hyperglycemia

fyi. bOB

Robert A. Browne MD, FACP
Senior Outcomes Research Advisor
U.S. Outcomes Research
Eli Lilly and Company
Lilly Corporate Center
Mail Drop 4025
Indianapolis, IN 46285
Phone: 317-276-9145
Fax: 317-277-7444
E-mail: browne_robert_a@lilly.com

----- Forwarded by Robert A Browne/AM/LLY on 09/13/2002 08:54 AM -----

Page: 2 of 3

Patrick A Toalson

09/12/2002 03:59 PM

To: Beth H Zimmerman/AM/LLY@Lilly, Bryan Johnstone/AM/LLY@Lilly, Dennis Myose/AM/LLY@Lilly, Irwin J Greenberg/AM/LLY@Lilly, James J Pierce/AM/LLY@Lilly, John Niewoehner/AM/LLY@Lilly, Karen Tohen/AM/LLY@Lilly, Kevin W Piezer/AM/LLY@Lilly, Lisa A Jatton/AM/LLY@Lilly, Luis Montanez/AM/LLY@LILLY, Michael A Bono/AM/LLY@Lilly, Patrick A Toalson/AM/LLY@Lilly, Rashmi S Yadav Marya/AM/LLY@Lilly, Shelethea M Dunning/AM/LLY@Lilly, Starr Grundy/AM/LLY@Lilly, Alison Potts/AM/LLY@Lilly, Carol A Toon/AM/LLY@Lilly, Britton Ashley Hill/AM/LLY@Lilly, Heidi S Wirtz/AM/LLY@Lilly, Kimberly Javor Johnson/AM/LLY@Lilly, Komathi Stem/AM/LLY@Lilly

cc: Robert W Baker/AM/LLY@Lilly, Robert A Browne/AM/LLY@Lilly, Vicki Poole Hoffmann/AM/LLY@Lilly

Subject: Label changes related to hyperglycemia

MLs,

FYI, attached is text of a note I got from Matt Pike concerning the changes to competitor PIs around hyperglycemia. I converted this to a word document from an email in case you wished to save the info. This is not intended for proactive discussions but rather to address a response should you be asked by a thought leader about what is going on with competitor labels.

Patrick Toalson R.Ph.
Neuroscience Medical Liaison
US Medical Division
ELI LILLY AND COMPANY
205-981-7799 Office
205-981-9742 Fax

redacted

Email: P.Toalson@lilly.com

[attachment "Hyperglycemia PI changes.doc" has been removed by Jerry D Clewell/AM/LLY]

Page: 3 of 3